7 It has been shown that GLP-1 receptors in the choroid plexus alter Na+/K+-ATPase activity, which directly influences CSF production and may reduce ICP without exclusively depending on weight reduction
In clinical trials, it has demonstrated significant weight loss effects, leading to its FDA approval for the following indication and usage: WEGOVY is a glucagon-like peptide-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: adult patients with an initial body mass index of 30 kg/m2 or greater or 27 kg/m2 or greater in the presence of at least one weight-related comorbid condition
The risk of accidental muscle injection with a pre-filled pen is very low
How long does it take to work
The optimal timing for semaglutide administration differs significantly between the injectable and oral formulations, and following manufacturer guidelines is essential for achieving maximum therapeutic effect
They may also reduce the risk of heart disease, kidney issues, and sleep apnea
00213-0/asset/596e56d2-b192-4136-acc3-480479499885/main.assets/gr3.jpg)
